- Home
- COCH vs PULM Comparison
COCH vs PULM Comparison
Compare COCH & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- PULM
- Stock Information
- Founded
- COCH 1995
- PULM 2003
- Country
- COCH United States
- PULM United States
- Employees
- COCH N/A
- PULM N/A
- Industry
- COCH Blank Checks
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- PULM Health Care
- Exchange
- COCH Nasdaq
- PULM Nasdaq
- Market Cap
- COCH 31.6M
- PULM 33.2M
- IPO Year
- COCH N/A
- PULM N/A
- Fundamental
- Price
- COCH $1.55
- PULM $6.61
- Analyst Decision
- COCH Strong Buy
- PULM
- Analyst Count
- COCH 2
- PULM 0
- Target Price
- COCH $9.25
- PULM N/A
- AVG Volume (30 Days)
- COCH 21.8K
- PULM 62.2K
- Earning Date
- COCH 08-11-2025
- PULM 08-12-2025
- Dividend Yield
- COCH N/A
- PULM N/A
- EPS Growth
- COCH N/A
- PULM N/A
- EPS
- COCH N/A
- PULM N/A
- Revenue
- COCH $212,000.00
- PULM $1,921,000.00
- Revenue This Year
- COCH $8.04
- PULM N/A
- Revenue Next Year
- COCH $15.39
- PULM $134.88
- P/E Ratio
- COCH N/A
- PULM N/A
- Revenue Growth
- COCH N/A
- PULM N/A
- 52 Week Low
- COCH $1.21
- PULM $1.78
- 52 Week High
- COCH $3.99
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- COCH 43.84
- PULM 39.23
- Support Level
- COCH $1.36
- PULM $6.65
- Resistance Level
- COCH $1.53
- PULM $7.20
- Average True Range (ATR)
- COCH 0.08
- PULM 0.91
- MACD
- COCH 0.00
- PULM -0.21
- Stochastic Oscillator
- COCH 27.78
- PULM 43.49
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).